Influence of Body Composition, Total Body Fat and Body Mass Index on the Pharmacokinetics of Docetaxel in Localized Breast Cancer
Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
The purpose of this study is to determine if pharmacokinetics of docetaxel is modified by the body composition (assessed by the BMI but also by CT-scan) in patients treated by docetaxel as adjuvant treatment of a localized breast cancer
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Healthy Volunteers: f
View:
• Woman older than
• Early breast cancer
• CT-scan of less than 3 months, including L3 level
• Indication of docetaxel at 100 mg/m² as adjuvant CT
Locations
Other Locations
France
Centre Henri Becquerel
RECRUITING
Rouen
Contact Information
Primary
Florian Clatot, Prof
florian.clatot@chb.unicancer.fr
+33232082231
Backup
Doriane Richard, PhD
doriane.richard@chb.unicancer.fr
+33232082985
Time Frame
Start Date: 2023-10-25
Estimated Completion Date: 2027-05-02
Participants
Target number of participants: 48
Treatments
Experimental: Pharmocokinetics blood sample assessment
during first administration of docetaxel several pharmacokinetics samples will be assessed
Related Therapeutic Areas
Sponsors
Leads: Centre Henri Becquerel
Collaborators: Universitaire Ziekenhuizen KU Leuven, Erasmus Medical Center